Stocks · News reference

Enanta Pharma Advances Zelicapavir Into Registrational Phase 2b/3 Clinical Trial In Adults At High Risk Of Severe Outcomes From RSV Infection After End-Of-Phase 2 Meeting With FDA

Jun 18, 2026, 11:06 AMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 10, 2026, 8:05 PMBenzinga Newsdesk
Enanta Pharma Q3 EPS $(0.67) Misses $(0.54) Estimate, Sales $14.359M Miss $16.796M Estimate
Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.54) by 26.42 percent. This is a 21.18 percent increase over losses of $(0.85) per share from
ENTA
BenzingaJul 2, 2026, 8:58 PMBenzinga Newsdesk
Enanta Pharmaceuticals Enters Open Market Sale Agreement With Jefferies; May Offer And Sell Up To $75M Of Common Stock Through Jefferies
ENTA
SEC EDGARJul 2, 2026, 8:56 PMSEC EDGAR
8-K filing — ENANTA PHARMACEUTICALS INC (ENTA)
Filed: 2026-07-02 AccNo: 0001193125-26-294837 Size: 426 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
ENTA
BenzingaJun 23, 2026, 3:32 PMBenzinga Newsdesk
'Pfizer Keeps Win in Patent Lawsuit Aimed at Paxlovid Antiviral' - Bloomberg
ENTA PFE